e
individual response to multiple antiplatelet agents. Addressing every major
antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R),
ReoPro(R), and Integrilin(R), the VerifyNow system provides a valuable tool
to help guide treatment decisions.
CONTACT: Steven Frankel, 858-404-8201, sfrankel@accumetrics.com.
Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix
is a registered trademark of Sanofi-Aventis.
'/>"/>SOURCE Accumetrics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial2.
ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results3.
Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device4.
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections5.
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR6.
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting7.
XTENT Announces European Regulatory Update8.
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity9.
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder10.
Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells11.
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology